WHO WE ARE

We are a dual-listed (Euronext Brussels and NASDAQ: TIG) biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions in areas of high unmet medical need.

17 May 2017

TiGenix to participate at international scientific and industry conferences (ENNLFRES)

12 May 2017

Convening notice to the extraordinary shareholders’ meeting to be held on 1 June 2017 (EN – NL)

UPCOMING EVENTS

  • INVESTORS AND BD
  • SCIENTIFIC AND OTHERS

SHARE PRICE

NASDAQ
17.00 USD
Change (%):
0.10 (0.59%)
BRU
0.77 EUR
Change (%):
0.00 (0.13%)

We use cookies to improve the website and your navigation experience based on our Terms of Use. To accept cookies continue to browse the site or click the accept button. If you do not want cookies to be set, modify your browser’s settings so that it will not accept cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close